HOME >> BIOLOGY >> NEWS
Rimonbant shows promise in addressing multiple risk factors

Quebec City, Canada, March 9, 2004 - Results of a Phase III clinical trial (RIO-Lipids or Rimonabant In Obesity) comparing rimonabant, the first drug in a new class called Selective CB1 Blockers (or SCB1Bs), to placebo found that overweight or obese patients with untreated dyslipidemia (high triglycerides, low HDL-cholesterol) lost almost 20 lbs (8.6 kg) when treated for a year with rimonabant 20mg. Weight loss was accompanied by a decrease in waist size of 3.4 inches (9.1 cm) demonstrating a significant reduction in abdominal obesity, an independent marker for heart disease. Dramatic improvements were also seen in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides. Improvements in glucose tolerance and insulin levels were also observed. In another important finding, the number of patients diagnosed at baseline with metabolic syndrome,1 who were treated with rimonabant 20mg, was reduced by half. The drug was also found to be safe and well-tolerated.

Rimonabant works by inhibiting the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System), believed to play a critical role in the regulation of food intake and energy expenditure.

"While the weight loss was clinically relevant, what is truly remarkable in the RIO-Lipids study is the significant effect rimonabant had on improving associated cardiovascular risk factors," said Jean-Pierre Despr's, principal investigator for RIO-Lipids and Professor in the Department of Food Sciences and Nutrition and Medicine at Laval University, and Director of Research at the Quebec Heart Institute located at the Laval Hospital Center in Quebec City, Canada. "Rimonabant appears to have a direct effect on fat cells which may be contributing to the beneficial effects of this drug on abdominal obesity and associated risk factors. Couple this with the markedly
'"/>

Contact: Glenn Lehrman
glenn.lehrman@ketchum.com
917-533-5998
Ketchum
9-Mar-2004


Page: 1 2 3 4 5 6

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/3/2019)... ... October 02, 2019 , ... Connecticut Innovations (CI), Connecticut’s strategic ... Connecticut’s innovative, growing companies, today announced that it has closed on a $750,000 ... of the 2018 VentureClash competition. , The outlay is part ...
(Date:9/30/2019)... , ... September 30, 2019 , ... ... focused on increasing the capacity of life science organizations to accelerate innovation and ... Francisco, CA on October 4th. , What: Just 30 days to 21 CFR ...
(Date:9/30/2019)... FREDERICK, Md. (PRWEB) , ... ... ... a biotechnology market disrupter and leading supplier of innovative human mesenchymal stem/stromal ... Australia for novel product formulations related to “Ready-to-Print” (RTP) cellular product formats ...
Breaking Biology News(10 mins):
(Date:10/10/2019)... ... 2019 , ... R3 Stem Cell announces it has added an exosome presentation ... Las Vegas with spots still open. , The speaker, Dr. Ian White PhD, is ... including Cornell, Harvard and Dartmouth. He currently serves as the Chief Scientific Officer at ...
(Date:10/3/2019)... (PRWEB) , ... October 01, 2019 , ... ... brain relax and reset itself, announced the midway point of its randomized research ... of the study is to measure the efficacy of a non-invasive technology which ...
(Date:10/3/2019)... (PRWEB) , ... October 02, 2019 , ... ... using mass spectrometry, is pleased to announce that it has moved into a ... among other analytical instruments, the new facility demonstrates the company's continuous commitment to ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health ... on the development of therapies to treat central nervous system (CNS) disorders, ...
Breaking Biology Technology:
Cached News: